

The FDA just delayed its decision on a subcutaneous version of Leqembi that could let Alzheimer's patients skip 39 IV infusions entirely. The three-month pushback to August 2026 matters more than it sounds, because the biggest barrier to Leqembi's success isn't the science; it's getting patients to show up.
Imagine you've been driving to the same clinic every two weeks for a year and a half. You sit in a chair, get hooked up to an IV, and wait an hour. Then you do it all over again, 39 times total. Now imagine someone tells you there's a version of the same drug you could inject at home in 15 seconds.
That's the promise behind subcutaneous Leqembi IQLIK, Eisai and Biogen's shot at making Alzheimer's treatment dramatically less painful. But the FDA just pumped the brakes.
The original plan was simple. The FDA had a decision date of May 24, 2026 for a new version of Leqembi: a weekly, self-administered shot that patients could use from day one of treatment instead of sitting through biweekly IV infusions.
Then, on May 8, Eisai disclosed that the FDA had requested additional information, classifying it as a "major amendment" to the application. That pushed the decision date back three months to August 24, 2026.
Eisai was quick to add some reassurance: the FDA hasn't raised concerns about whether the drug is actually approvable. The delay is about reviewing new data, not a red flag. But in biotech, three months is an eternity when you're trying to build commercial momentum.
To understand why Wall Street cares so much about a shot, you need to understand how miserable the current Leqembi experience is for patients.
The standard regimen requires IV infusions every two weeks for 18 months. Each visit means traveling to an infusion center, getting an IV placed, sitting for about an hour, and then waiting around for observation. Real-world chair time often stretches to two or three hours. You need a caregiver to drive you. You need a center that has capacity. And you need to do this roughly 39 times before switching to maintenance.
For an elderly patient with early Alzheimer's, that's not just inconvenient. It's a dealbreaker. Eisai aimed to treat 100,000 U.S. patients by 2026, but the actual numbers have been far lower. The company even , citing slower-than-expected U.S. uptake driven by infrastructure and logistical hurdles.

A Suzhou biotech just raised $80 million on the Hong Kong Stock Exchange to fight bacterial infections, an area most investors won't touch. Its lead drug crushed the standard of care for H. pylori in Phase III, and the company's hybrid chemistry platform could reshape how we treat everything from stomach bugs to infected hip implants.


Join thousands of biotech professionals who start their day with our free, daily briefing.
The subcutaneous version is supposed to fix all of this.
This is where it gets a little layered, so let's break it into two pieces.
Already approved: In August 2025, the FDA greenlit Leqembi IQLIK as a 360 mg weekly subcutaneous injection for maintenance. That means after you finish the grueling 18-month IV induction, you can switch to a simple weekly shot at home. Think of it like finishing physical therapy at the clinic and then doing your exercises at home.
Not yet approved: The pending application is for a 500 mg weekly subcutaneous starting dose (delivered as two 250 mg injections, each taking about 15 seconds). If approved, patients could skip the IV entirely and do the whole treatment course at home from the start.
That second piece is the game-changer. Jefferies analyst Michael Yee has characterized the SC maintenance approval as a "nice to have" but called SC induction "critical" for maximizing the franchise's value. Getting patients started at home, not just finishing at home, is what could truly unlock adoption.
From a science perspective, the subcutaneous version checks the important boxes. Weekly 500 mg shots achieved plasma exposure comparable to IV dosing, and the 90% confidence interval for drug exposure fell within the standard bioequivalence window of 80–125%.
In Eisai's open-label extension studies, patients starting on subcutaneous Leqembi actually showed about 14% greater amyloid plaque removal at six months compared to IV patients. The safety profile looked similar too, with systemic injection reactions occurring in less than 2% of participants.
The drug still carries a boxed warning for ARIA (amyloid-related imaging abnormalities, essentially brain swelling or microbleeds that can occur when you clear amyloid). Patients will still need MRI monitoring regardless of how they receive the drug. But they won't need to drive to an infusion center twice a month.
Leqembi doesn't exist in a vacuum. Eli Lilly's Kisunla (donanemab), approved in July 2024, is the main rival. Both drugs target amyloid plaques in early Alzheimer's, but they play the game differently.
Kisunla's pitch is "treat and done." It's an IV infusion once a month, and about 70% of patients can stop treatment entirely around 18 months once their amyloid PET scans come back clean. No indefinite maintenance. Lilly prices it at roughly $32,000 per year, compared to Leqembi's $26,500 for IV (and about $19,500 for the subcutaneous version).
Leqembi's counter-pitch is convenience through route of administration. Once SC induction is approved, the entire treatment journey could happen at home. No infusion center, no IV lines, no monthly hospital visits. For a patient population that struggles with transportation and caregiver logistics, that's a powerful argument.
Leqembi held roughly 67% of the anti-amyloid market in 2024, helped by its earlier approval and more established clinical pathways. The SC advantage could widen that lead.
But Lilly isn't standing still. Its next-generation candidate, remternetug, is in Phase 3 trials with both SC and IV options built in from the start. If it works, Lilly could match Leqembi's convenience while keeping the "finite course" appeal of donanemab.
The anti-amyloid antibody market represents a massive prize, and how patients actually receive these drugs will determine who captures it.
The August 24 PDUFA date is now the binary event that analysts are circling on their calendars. A positive decision would mean Leqembi can be prescribed as an entirely at-home therapy.
For patients and their families, the stakes are simpler. Every two weeks, someone with early Alzheimer's has to organize a ride, sit in a clinic, and endure an infusion that reminds them they're sick. A 15-second shot at the kitchen table won't cure the disease. But it might keep a lot more people on the treatment that slows it down.
Three more months of waiting. For a drug designed to fight a disease that steals time, the irony stings.
Isomorphic Labs, the Google DeepMind spinoff, just raised $2.1 billion in the largest AI drug discovery financing ever. With Nobel Prize-winning science, $3 billion in pharma deals, and zero approved drugs, the company is making the biggest bet the field has ever seen.